Engineering (Bispecific) Antibodies for Cancer and Immunotherapy

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 4444

Special Issue Editor

Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
Interests: immunotherapy of cancer; bispecific antibodies; T cell bispecific antibodies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

While in the past decades the majority of biological agents in development for therapeutic purposes have been based on classical antibodies, more recently the field has experienced a major increase in the introduction of engineered and bispecific antibodies that mediate novel functions and have differentiated mechanisms of action. Consequently, engineered and bispecific antibodies have become dominant topics in academic and pharmaceutical therapeutic antibody research and development. This Special Issue of Antibodies aims to collect original manuscripts and reviews covering the progress in the broad field of engineered (bispecific) antibodies, including antibody fusion proteins and immunocytokines, with a focus on their therapeutic application in cancer (immuno-) therapy, as well as in therapy for autoimmune and infectious diseases.

Dr. Christian Klein
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • engineered antibodies
  • bispecific antibodies
  • antibody fusion proteins
  • immunocytokines
  • cancer therapy
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 318 KiB  
Review
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
Antibodies 2022, 11(2), 22; https://doi.org/10.3390/antib11020022 - 24 Mar 2022
Cited by 1 | Viewed by 3599
Abstract
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with [...] Read more.
Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM. Full article
(This article belongs to the Special Issue Engineering (Bispecific) Antibodies for Cancer and Immunotherapy)
Back to TopTop